Autoimmune Life Blog

Learn how CRISPR-Cas9-based genome engineering using adeno-associated virus (AAV) vectors is helping BRI scientists make breakthroughs to study human T cells and explore new treatments for type 1 diabetes, as well as  develop preclinical models to study T cells and B cell

At first, Cate Speake, PhD, and her team weren’t sure that a mysterious phenomenon called autoantibody reversion was actually happening. But no matter how they sliced the data, they saw the same pattern. Learn how autoantibody reversion could unlock new clues to preventing type 1 diabetes.

Learn how lab-grown human beta cells are helping Eddie James, PhD, and other BRI researchers answer important questions in type 1 diabetes. 

Find out about new advances in autoimmune disease screening from a team led by Cate Speake, PhD.

Read exciting updates and learn what’s on the horizon for 2025 from BRI President Jane Buckner, MD.

Dr. Smithmyer is a staff scientist at Benaroya Research Institute (BRI) in the Center for Interventional Immunology. She has kindly agreed to speak with us about what the BRIDge Biorepository is and its importance to the work that scientists like her do in the realm of type 1 diabetes.

BRI investigators Eddie James, PhD, and Caroline Stefani, PhD, are teaming up to take a unique approach to type 1 diabetes research.

Learn about exciting new type 1 diabetes research Dr. Griffin is taking on at BRI.

Learn how a team led by Carla Greenbaum, MD, is using “fancy math” to better understand not only if a person will develop T1D, but when.

June 1, 2024, marked the second annual Benaroya Research Institute T1D Family Day.